State of Alaska Department of Revenue Decreases Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

State of Alaska Department of Revenue lowered its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,781 shares of the company’s stock after selling 544 shares during the quarter. State of Alaska Department of Revenue’s holdings in Amphastar Pharmaceuticals were worth $602,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. Exchange Traded Concepts LLC purchased a new position in shares of Amphastar Pharmaceuticals in the first quarter worth $257,000. CX Institutional purchased a new position in shares of Amphastar Pharmaceuticals in the first quarter worth $2,381,000. GAMMA Investing LLC raised its stake in shares of Amphastar Pharmaceuticals by 46.6% in the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock worth $39,000 after purchasing an additional 424 shares during the last quarter. Bridge City Capital LLC raised its stake in shares of Amphastar Pharmaceuticals by 65.3% in the first quarter. Bridge City Capital LLC now owns 115,855 shares of the company’s stock worth $3,359,000 after purchasing an additional 45,760 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Amphastar Pharmaceuticals by 1.9% in the first quarter. Rhumbline Advisers now owns 88,958 shares of the company’s stock worth $2,579,000 after purchasing an additional 1,631 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 0.4%

Amphastar Pharmaceuticals stock opened at $23.08 on Friday. The stock has a market cap of $1.09 billion, a PE ratio of 8.36, a price-to-earnings-growth ratio of 6.01 and a beta of 0.77. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.02 and a current ratio of 2.95. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96. The stock has a fifty day moving average of $24.79 and a 200 day moving average of $29.49.

Analyst Ratings Changes

AMPH has been the subject of a number of research reports. Piper Sandler reduced their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Friday, March 21st. Wells Fargo & Company reduced their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday, May 8th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $32.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.